• Oncotelic Therapeutics granted 17,796 restricted stock units in an unregistered equity issuance exempt under Securities Act Section 4(a)(2).
• Each RSU settles into 1 share of Series A Convertible Preferred Stock, convertible into 1,000 common shares.
• Vesting requires a common-stock uplisting to a national exchange by June 30, 2027, then six months of continued service.
• RSUs were issued at no cost; awards cover directors, officers, employees, and advisers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncotelic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-033171), on July 14, 2026, and is solely responsible for the information contained therein.